Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

The FDA approved calaspargase pegol-mknl, an asparagine-specific enzyme, for the treatment of pediatric and young adult patients (ages 1 month to 21 years) with...

Predicting Response to Alvocidib in Patients With Relapsed/Refractory AML

The CDK9 inhibitor alvocidib induced a high rate of responses in patients with relapsed or refractory acute myeloid leukemia (AML) who had MCL1-dependent disease,...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
WIB_icon

Azacitidine Maintenance Improves Disease-Free Survival in Older Patients with Newly Diagnosed AML

Older patients with acute myeloid leukemia (AML) in complete remission (CR) who received maintenance therapy with subcutaneous azacitidine had longer disease-free survival (DFS), compared...

Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...

For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...

FDA Approves Gilteritinib for FLT3-Mutated AML

The oral FLT3/AXL inhibitor gilteritinib was approved by the FDA for the treatment of adult patients with FLT3-mutated, relapsed or refractory AML. The FDA...

SHARE